In this issue:
Leukaemia selection
Immune escape of relapsed AML cells after allogeneic SCT
Foetal haemoglobin induction during decitabine for elderly MDS/AML
Lower ibrutinib doses for CLL
First-line ibrutinib or chlorambucil with obinutuzumab for CLL
Lymphoma selection
Outcome-based interpretation of early PET in advanced Hodgkin’s lymphoma
Short response duration after follicular lymphoma relapse in the rituximab era
Tisagenlecleucel in relapsed/refractory DLBCL
Brentuximab vedotin + chemotherapy for CD30+ peripheral T-cell lymphoma
Genomic alterations important for follicular lymphoma prognosis
Please login below to download this issue (PDF)